Mechanisms of neurodegeneration in Huntington’s disease
暂无分享,去创建一个
[1] Jennifer Goldman,et al. Huntington disease , 2010, Principles and Practice of Movement Disorders.
[2] S. Kuo,et al. Depletion of mitochondrial DNA in leukocytes of patients with poly-Q diseases , 2008, Journal of the Neurological Sciences.
[3] F. Melchior,et al. Concepts in sumoylation: a decade on , 2007, Nature Reviews Molecular Cell Biology.
[4] L. Raymond,et al. Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load , 2007, The Journal of physiology.
[5] S. Hersch,et al. Neuroprotective Effects of Synaptic Modulation in Huntington's Disease R6/2 Mice , 2007, The Journal of Neuroscience.
[6] R. Atwal,et al. Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. , 2007, Human molecular genetics.
[7] J. Olson,et al. Expression Profiling of Huntington's Disease Models Suggests That Brain-Derived Neurotrophic Factor Depletion Plays a Major Role in Striatal Degeneration , 2007, The Journal of Neuroscience.
[8] J. Cooper,et al. Clinical correlates of mitochondrial function in Huntington's disease muscle , 2007, Movement disorders : official journal of the Movement Disorder Society.
[9] S. Schreiber,et al. Small Molecule Enhancers of Rapamycin-Induced TOR Inhibition Promote Autophagy, Reduce Toxicity in Huntington’s Disease Models and Enhance Killing of Mycobacteria by Macrophages , 2007, Autophagy.
[10] Howard Schulman,et al. Global changes to the ubiquitin system in Huntington's disease , 2007, Nature.
[11] Yih-Ru Wu,et al. Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients. , 2007, Biochemical and biophysical research communications.
[12] Xi Chen,et al. Dopaminergic Signaling and Striatal Neurodegeneration in Huntington's Disease , 2007, The Journal of Neuroscience.
[13] Alexandra Durr,et al. Early Energy Deficit in Huntington Disease: Identification of a Plasma Biomarker Traceable during Disease Progression , 2007, PloS one.
[14] T. Videen,et al. Normal platelet mitochondrial complex I activity in Huntington’s Disease , 2007, Neurobiology of Disease.
[15] M. Hayden,et al. Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington’s disease , 2007, Neuroscience.
[16] S. Schreiber,et al. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. , 2007, Nature chemical biology.
[17] J. Olson,et al. Huntingtin Interacting Proteins Are Genetic Modifiers of Neurodegeneration , 2007, PLoS genetics.
[18] J. Roder,et al. NMDA Receptor Function and NMDA Receptor-Dependent Phosphorylation of Huntingtin Is Altered by the Endocytic Protein HIP1 , 2007, The Journal of Neuroscience.
[19] D. Rubinsztein,et al. Trehalose, a Novel mTOR-independent Autophagy Enhancer, Accelerates the Clearance of Mutant Huntingtin and α-Synuclein* , 2007, Journal of Biological Chemistry.
[20] M. MacDonald,et al. Huntingtin inhibits caspase‐3 activation , 2006, The EMBO journal.
[21] A. Parent,et al. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea. , 2006, Brain : a journal of neurology.
[22] M. Russo,et al. Increased apoptosis, huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington's disease subjects , 2006, Cell Death and Differentiation.
[23] Shihua Li,et al. Context-dependent Dysregulation of Transcription by Mutant Huntingtin* , 2006, Journal of Biological Chemistry.
[24] S. Luquet,et al. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. , 2006, Cell metabolism.
[25] M. Hayden,et al. Mitochondrial-Dependent Ca2+ Handling in Huntington's Disease Striatal Cells: Effect of Histone Deacetylase Inhibitors , 2006, The Journal of Neuroscience.
[26] Jiandie D. Lin,et al. Suppression of Reactive Oxygen Species and Neurodegeneration by the PGC-1 Transcriptional Coactivators , 2006, Cell.
[27] Dimitri Krainc,et al. Transcriptional Repression of PGC-1α by Mutant Huntingtin Leads to Mitochondrial Dysfunction and Neurodegeneration , 2006, Cell.
[28] C. Ross,et al. Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin , 2006, Neurobiology of Disease.
[29] F. Jiménez-Jiménez,et al. Oxidative Stress in Skin Fibroblasts Cultures of Patients with Huntington’s Disease , 2006, Neurochemical Research.
[30] Michael P. Cusack,et al. Huntingtin Phosphorylation Sites Mapped by Mass Spectrometry , 2006, Journal of Biological Chemistry.
[31] M. MacDonald,et al. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice , 2006, Neurobiology of Disease.
[32] L. Raymond,et al. Cleavage at the Caspase-6 Site Is Required for Neuronal Dysfunction and Degeneration Due to Mutant Huntingtin , 2006, Cell.
[33] Wei Li,et al. Expression and Characterization of Full-length Human Huntingtin, an Elongated HEAT Repeat Protein* , 2006, Journal of Biological Chemistry.
[34] S. Augood,et al. Huntingtin inclusions do not down‐regulate specific genes in the R6/2 Huntington's disease mouse , 2006, The European journal of neuroscience.
[35] Alexei Degterev,et al. Regulation of Intracellular Accumulation of Mutant Huntingtin by Beclin 1* , 2006, Journal of Biological Chemistry.
[36] S. Tabrizi,et al. Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. , 2006, Human molecular genetics.
[37] Lu Gan,et al. Palmitoylation of huntingtin by HIP14is essential for its trafficking and function , 2006, Nature Neuroscience.
[38] M. MacDonald,et al. Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease , 2006, Neurobiology of Disease.
[39] M. DiFiglia,et al. Lysosomal proteases are involved in generation of N-terminal huntingtin fragments , 2006, Neurobiology of Disease.
[40] C. Oliveira,et al. Caspase‐dependent and ‐independent cell death induced by 3‐nitropropionic acid in rat cortical neurons , 2006, Journal of cellular biochemistry.
[41] M. Levine,et al. Changes in Expression of N-Methyl-D-Aspartate Receptor Subunits Occur Early in the R6/2 Mouse Model of Huntington’s Disease , 2006, Developmental Neuroscience.
[42] O. Riess,et al. Normal sensitivity to excitotoxicity in a transgenic Huntington's disease rat , 2006, Brain Research Bulletin.
[43] J. Olson,et al. Regional and cellular gene expression changes in human Huntington's disease brain. , 2006, Human molecular genetics.
[44] J. Rothman,et al. Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway , 2006, The Journal of cell biology.
[45] Xiao-Jiang Li,et al. Interaction of Huntingtin-associated Protein-1 with Kinesin Light Chain , 2006, Journal of Biological Chemistry.
[46] L. Thompson,et al. Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation , 2006, Mechanisms of Ageing and Development.
[47] D. Rubinsztein,et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. , 2006, Human molecular genetics.
[48] Andrea Ciarmiello,et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[49] M. Hayden,et al. Wild‐type huntingtin protects neurons from excitotoxicity , 2006, Journal of neurochemistry.
[50] Ji-Yeon Shin,et al. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity , 2005, The Journal of cell biology.
[51] R. Kopito,et al. HDAC6 and Microtubules Are Required for Autophagic Degradation of Aggregated Huntingtin* , 2005, Journal of Biological Chemistry.
[52] D. Blum,et al. 3‐Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease , 2005, Journal of neurochemistry.
[53] C. Cepeda,et al. Alterations in N‐methyl‐D‐aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease , 2005, Journal of neuroscience research.
[54] M. MacDonald,et al. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. , 2005, Human molecular genetics.
[55] J. Pruim,et al. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease , 2005, Neurology.
[56] Atsushi Iwata,et al. Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[57] B Fischl,et al. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition , 2005, Neurology.
[58] G. Johnson,et al. Mitochondrial Respiration and ATP Production Are Significantly Impaired in Striatal Cells Expressing Mutant Huntingtin* , 2005, Journal of Biological Chemistry.
[59] Josephine C. Dorsman,et al. Mutant huntingtin represses CBP, but not p300, by binding and protein degradation , 2005, Molecular and Cellular Neuroscience.
[60] C. Pagès,et al. Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[61] M. Hayden,et al. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[62] S. Snyder,et al. p53 Mediates Cellular Dysfunction and Behavioral Abnormalities in Huntington’s Disease , 2005, Neuron.
[63] P. Brundin,et al. Synaptic dysfunction in Huntington’s disease: a new perspective , 2005, Cellular and Molecular Life Sciences CMLS.
[64] B. Landwehrmeyer,et al. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.
[65] Lu Gan,et al. Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. , 2005, Human molecular genetics.
[66] D. Rubinsztein,et al. Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases , 2005, The Journal of cell biology.
[67] Paolo Guidetti,et al. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease , 2005, Nature Genetics.
[68] S. Nemoto,et al. SIRT1 Functionally Interacts with the Metabolic Regulator and Transcriptional Coactivator PGC-1α* , 2005, Journal of Biological Chemistry.
[69] M. Panas,et al. Plasma testosterone in male patients with Huntington's disease: Relations to severity of illness and dementia , 2005, Annals of neurology.
[70] Christian Néri,et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons , 2005, Nature Genetics.
[71] M. Levine,et al. Age-dependent biphasic changes in ischemic sensitivity in the striatum of Huntington's disease R6/2 transgenic mice. , 2005, Journal of neurophysiology.
[72] J. Epplen,et al. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease , 2005, Neurogenetics.
[73] Carlos Cepeda,et al. Increased GABAergic function in mouse models of Huntington's disease: Reversal by BDNF , 2004, Journal of neuroscience research.
[74] S. Augood,et al. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease , 2004, Neurobiology of Disease.
[75] C. Oliveira,et al. FK506 prevents mitochondrial-dependent apoptotic cell death induced by 3-nitropropionic acid in rat primary cortical cultures , 2004, Neurobiology of Disease.
[76] Mark R. Segal,et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death , 2004, Nature.
[77] G. Bates,et al. Huntingtin and the molecular pathogenesis of Huntington's disease , 2004, EMBO reports.
[78] M. MacDonald,et al. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. , 2004, Human molecular genetics.
[79] Fabrice P Cordelières,et al. Huntingtin Controls Neurotrophic Support and Survival of Neurons by Enhancing BDNF Vesicular Transport along Microtubules , 2004, Cell.
[80] Peter Breuer,et al. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. , 2004, Molecular cell.
[81] I. Kohane,et al. Gene regulation and DNA damage in the ageing human brain , 2004, Nature.
[82] E. Nagata,et al. Autophagosome-like vacuole formation in Huntington's disease lymphoblasts , 2004, Neuroreport.
[83] J. Penney,et al. Differential loss of striatal projection systems in Huntington’s disease: a quantitative immunohistochemical study , 2004, Journal of Chemical Neuroanatomy.
[84] Francesco Scaravilli,et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease , 2004, Nature Genetics.
[85] P. Pandolfi,et al. SUMO Modification of Huntingtin and Huntington's Disease Pathology , 2004, Science.
[86] J. Pedraza-Chaverri,et al. Increased Formation of Reactive Oxygen Species, but No Changes in Glutathione Peroxidase Activity, in Striata of Mice Transgenic for the Huntington's Disease Mutation , 2004, Neurochemical Research.
[87] Karen Marder,et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[88] Xiao-Jiang Li,et al. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. , 2004, Trends in genetics : TIG.
[89] Wilhelm Gaus,et al. Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis , 2004, Neurology.
[90] M. MacDonald,et al. The serum‐ and glucocorticoid‐induced kinase SGK inhibits mutant huntingtin‐induced toxicity by phosphorylating serine 421 of huntingtin , 2004, The European journal of neuroscience.
[91] L. Thompson,et al. Autophagy regulates the processing of amino terminal huntingtin fragments. , 2003, Human molecular genetics.
[92] David W. Miller,et al. Analysis of cellular, transgenic and human models of Huntington's disease reveals tyrosine hydroxylase alterations and substantia nigra neuropathology. , 2003, Brain research. Molecular brain research.
[93] Aaron Ciechanover,et al. The Ubiquitin Proteasome System in Neurodegenerative Diseases Sometimes the Chicken, Sometimes the Egg , 2003, Neuron.
[94] C. Oliveira,et al. Mitochondrial Dysfunction and Reactive Oxygen Species in Excitotoxicity and Apoptosis: Implications for the Pathogenesis of Neurodegenerative Diseases , 2003, Neurochemical Research.
[95] Patrik Brundin,et al. Huntington's disease: a synaptopathy? , 2003, Trends in molecular medicine.
[96] Susanna M. Grzeschik,et al. Neurodegeneration in Striatum Induced by the Mitochondrial Toxin 3-Nitropropionic Acid: Role of Matrix Metalloproteinase-9 in Early Blood-Brain Barrier Disruption? , 2003, The Journal of Neuroscience.
[97] Andrea Crotti,et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes , 2003, Nature Genetics.
[98] C. Parsons,et al. Expression of Polyglutamine-expanded Huntingtin Induces Tyrosine Phosphorylation of N-Methyl-D-aspartate Receptors* , 2003, Journal of Biological Chemistry.
[99] E. Marcora,et al. Stimulation of NeuroD activity by huntingtin and huntingtin-associated proteins HAP1 and MLK2 , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[100] M. Hayden,et al. Huntingtin and Huntingtin-Associated Protein 1 Influence Neuronal Calcium Signaling Mediated by Inositol-(1,4,5) Triphosphate Receptor Type 1 , 2003, Neuron.
[101] M. Chesselet,et al. The use of transgenic and knock-in mice to study Huntington’s disease , 2003, Cytogenetic and Genome Research.
[102] H. Paulson,et al. Protein aggregation and the ubiquitin proteasome pathway: gaining the UPPer hand on neurodegeneration. , 2003, Current opinion in genetics & development.
[103] N Makris,et al. Evidence for more widespread cerebral pathology in early HD , 2003, Neurology.
[104] D. Rubinsztein,et al. Transcriptional abnormalities in Huntington disease. , 2003, Trends in genetics : TIG.
[105] M. Rechsteiner,et al. Are Huntington's and polyglutamine-based ataxias proteasome storage diseases? , 2003, The international journal of biochemistry & cell biology.
[106] M. Chesselet,et al. Apoptosis in Huntington's disease , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[107] Carlos Cepeda,et al. Transient and Progressive Electrophysiological Alterations in the Corticostriatal Pathway in a Mouse Model of Huntington's Disease , 2003, The Journal of Neuroscience.
[108] A. Young. Huntingtin in health and disease. , 2003, The Journal of clinical investigation.
[109] K. Marder,et al. Weight loss in early stage of Huntington’s disease , 2002, Neurology.
[110] D. Tagle,et al. PACSIN 1 interacts with huntingtin and is absent from synaptic varicosities in presymptomatic Huntington's disease brains. , 2002, Human molecular genetics.
[111] C. Ross,et al. Polyglutamine Repeat Length-Dependent Proteolysis of Huntingtin , 2002, Neurobiology of Disease.
[112] B. Escalante,et al. Age-dependent changes in nitric oxide synthase activity and protein expression in striata of mice transgenic for the Huntington’s disease mutation , 2002, Brain Research.
[113] F. Squitieri,et al. CAG mutation effect on rate of progression in Huntington's disease , 2002, Neurological Sciences.
[114] James R. Burke,et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines , 2002, Nature Neuroscience.
[115] L. Ellerby,et al. Calpain Activation in Huntington's Disease , 2002, The Journal of Neuroscience.
[116] A. Deckel,et al. Altered neuronal nitric oxide synthase expression contributes to disease progression in Huntington’s disease transgenic mice , 2002, Brain Research.
[117] Fabrice P Cordelières,et al. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. , 2002, Developmental cell.
[118] Dimitri Krainc,et al. Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease , 2002, Science.
[119] P. Brundin,et al. Maintenance of Susceptibility to Neurodegeneration Following Intrastriatal Injections of Quinolinic Acid in a New Transgenic Mouse Model of Huntington's Disease , 2002, Experimental Neurology.
[120] Rainer Duden,et al. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. , 2002, Human molecular genetics.
[121] L. Raymond,et al. Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease , 2002, Neuron.
[122] A. Dale,et al. Regional and progressive thinning of the cortical ribbon in Huntington’s disease , 2002, Neurology.
[123] Pascal Kahlem,et al. Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with beta-tubulin: relevance to Huntington's disease. , 2002, Journal of cell science.
[124] J. Nevins,et al. Huntingtin Is Present in the Nucleus, Interacts with the Transcriptional Corepressor C-terminal Binding Protein, and Represses Transcription* , 2002, The Journal of Biological Chemistry.
[125] He Li,et al. Interaction of Huntington Disease Protein with Transcriptional Activator Sp1 , 2002, Molecular and Cellular Biology.
[126] M. Tsai,et al. Neogenesis of β-cells in adult BETA2/NeuroD-deficient mice , 2002 .
[127] A. Hackam,et al. Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi , 2002, Nature Cell Biology.
[128] G. Rebec,et al. Dysregulation of Ascorbate Release in the Striatum of Behaving Mice Expressing the Huntington's Disease Gene , 2002, The Journal of Neuroscience.
[129] C. Cepeda,et al. Changes in Cortical and Striatal Neurons Predict Behavioral and Electrophysiological Abnormalities in a Transgenic Murine Model of Huntington's Disease , 2001, The Journal of Neuroscience.
[130] A. Deckel,et al. Reduced activity and protein expression of NOS in R6/2 HD transgenic mice: effects of l-NAME on symptom progression , 2001, Brain Research.
[131] C. Cepeda,et al. NMDA receptor function in mouse models of Huntington disease , 2001, Journal of neuroscience research.
[132] R. Hen,et al. Proteasomal-Dependent Aggregate Reversal and Absence of Cell Death in a Conditional Mouse Model of Huntington's Disease , 2001, The Journal of Neuroscience.
[133] G. Bernardi,et al. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene , 2001, The European journal of neuroscience.
[134] Z. Qin,et al. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[135] A. Mahal,et al. Impaired Glutamate Uptake in the R6 Huntington's Disease Transgenic Mice , 2001, Neurobiology of Disease.
[136] A. Morton,et al. Abnormalities in the synaptic vesicle fusion machinery in Huntington’s disease , 2001, Brain Research Bulletin.
[137] R. Albin,et al. Vesicular neurotransmitter transporters in Huntington's disease: Initial observations and comparison with traditional synaptic markers , 2001, Synapse.
[138] O. Hansson,et al. Partial resistance to malonate‐induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length , 2001, Journal of neurochemistry.
[139] P. Reddy,et al. Polyglutamine-expanded Huntingtin Promotes Sensitization of N-Methyl-d-aspartate Receptors via Post-synaptic Density 95* , 2001, The Journal of Biological Chemistry.
[140] L. Bäckman,et al. Dopamine and cognitive functioning: brain imaging findings in Huntington's disease and normal aging. , 2001, Scandinavian journal of psychology.
[141] A. Sawa. Mechanisms for neuronal cell death and dysfunction in Huntington's disease: pathological cross-talk between the nucleus and the mitochondria? , 2001, Journal of Molecular Medicine.
[142] D. Rigamonti,et al. Huntingtin's Neuroprotective Activity Occurs via Inhibition of Procaspase-9 Processing* , 2001, The Journal of Biological Chemistry.
[143] E A Zemskov,et al. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. , 2001, Human molecular genetics.
[144] D. Joel,et al. Open interconnected model of basal ganglia‐thalamocortical circuitry and its relevance to the clinical syndrome of Huntington's disease , 2001, Movement disorders : official journal of the Movement Disorder Society.
[145] H. Lehrach,et al. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. , 2001, Molecular biology of the cell.
[146] J. Pedraza-Chaverri,et al. Comparative Analysis of Superoxide Dismutase Activity between Acute Pharmacological Models and a Transgenic Mouse Model of Huntington's Disease , 2001, Neurochemical Research.
[147] K. Sieradzan,et al. The selective vulnerability of nerve cells in Huntington's disease , 2001, Neuropathology and applied neurobiology.
[148] T. Foroud,et al. Progression of symptoms in the early and middle stages of Huntington disease. , 2001, Archives of neurology.
[149] J. Hodgson,et al. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. , 2001, American journal of human genetics.
[150] Michael R. Hayden,et al. Mutant Huntingtin Enhances Excitotoxic Cell Death , 2001, Molecular and Cellular Neuroscience.
[151] A. Morton,et al. Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease , 2001, Journal of neurochemistry.
[152] D. Rubinsztein,et al. The molecular biology of Huntington's disease , 2001, Psychological Medicine.
[153] A. Tobin,et al. Huntington's disease: the challenge for cell biologists. , 2000, Trends in cell biology.
[154] Michael S. Levine,et al. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice , 2000, Nature Genetics.
[155] A. Morton,et al. Mice Transgenic for the Huntington's Disease Mutation Are Resistant to Chronic 3‐Nitropropionic Acid‐Induced Striatal Toxicity , 2000, Journal of neurochemistry.
[156] M. DiFiglia,et al. Huntingtin Expression Stimulates Endosomal–Lysosomal Activity, Endosome Tubulation, and Autophagy , 2000, The Journal of Neuroscience.
[157] A. F. Neuwald,et al. HEAT repeats associated with condensins, cohesins, and other complexes involved in chromosome-related functions. , 2000, Genome research.
[158] B. Halliwell,et al. No Evidence for Increased Oxidative Damage to Lipids, Proteins, or DNA in Huntington's Disease , 2000, Journal of neurochemistry.
[159] D. Manners,et al. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy , 2000, Annals of neurology.
[160] D. Housman,et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[161] A. Hackam,et al. Wild-Type Huntingtin Protects from Apoptosis Upstream of Caspase-3 , 2000, The Journal of Neuroscience.
[162] R. Albin,et al. Decreased striatal monoaminergic terminals in Huntington disease , 2000, Neurology.
[163] A. Morton,et al. Mice transgenic for the human Huntington’s disease mutation have reduced sensitivity to kainic acid toxicity , 2000, Brain Research Bulletin.
[164] D. Rubinsztein,et al. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[165] D. Lowenstein,et al. Loss of BETA2/NeuroD leads to malformation of the dentate gyrus and epilepsy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[166] K. Leenders,et al. Bradykinesia in early Huntington’s disease , 2000, Neurology.
[167] A H Schapira,et al. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse , 2000, Annals of neurology.
[168] J. D. de Yébenes,et al. Bradykinesia in Huntington's Disease , 2000, Clinical neuropharmacology.
[169] S. Hersch,et al. Huntingtin aggregates may not predict neuronal death in Huntington's disease , 1999 .
[170] S. Snyder,et al. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization , 1999, Nature Medicine.
[171] D. Sulzer,et al. Intraneuronal dopamine-quinone synthesis: A review , 1999, Neurotoxicity Research.
[172] O. Hansson,et al. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[173] D. Price,et al. Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[174] J. Penney,et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease , 1999, Nature.
[175] Claire-Anne Gutekunst,et al. Nuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology , 1999, The Journal of Neuroscience.
[176] J. Blenis,et al. Caspase-8 Is Required for Cell Death Induced by Expanded Polyglutamine Repeats , 1999, Neuron.
[177] J. Penney,et al. Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. , 1999, Journal of neuropathology and experimental neurology.
[178] S. Tabrizi,et al. Biochemical abnormalities and excitotoxicity in Huntington's disease brain , 1999, Annals of neurology.
[179] M. Beal,et al. Increased Vulnerability to 3‐Nitropropionic Acid in an Animal Model of Huntington's Disease , 1998, Journal of neurochemistry.
[180] J. Baldassare,et al. Molecular aspects of Huntington's disease , 1998, Journal of neuroscience research.
[181] Steven Finkbeiner,et al. Huntingtin Acts in the Nucleus to Induce Apoptosis but Death Does Not Correlate with the Formation of Intranuclear Inclusions , 1998, Cell.
[182] D. Shear,et al. Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease , 1998, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[183] M. Dragunow,et al. Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum , 1998, Neuroscience.
[184] M. MacDonald,et al. Huntingtin: a single bait hooks many species , 1998, Current Opinion in Neurobiology.
[185] S. W. Davies,et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[186] H. Green,et al. Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine. , 1998, Molecular cell.
[187] J. Arenas,et al. Complex I Defect in muscle from patients with Huntington's disease , 1998, Annals of neurology.
[188] F. Condé,et al. Partial Inhibition of Brain Succinate Dehydrogenase by 3‐Nitropropionic Acid Is Sufficient to Initiate Striatal Degeneration in Rat , 1998, Journal of neurochemistry.
[189] S. W. Davies,et al. Intranuclear Neuronal Inclusions in Huntington's Disease and Dentatorubral and Pallidoluysian Atrophy: Correlation between the Density of Inclusions andIT15CAG Triplet Repeat Length , 1998, Neurobiology of Disease.
[190] S. W. Davies,et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.
[191] K. Kinzler,et al. A model for p53-induced apoptosis , 1997, Nature.
[192] S. Augood,et al. Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease , 1997, Annals of neurology.
[193] M. Beal,et al. Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia , 1997, Annals of neurology.
[194] M. MacDonald,et al. Heterogeneous Topographic and Cellular Distribution of Huntingtin Expression in the Normal Human Neostriatum , 1997, The Journal of Neuroscience.
[195] S. Palfi,et al. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid , 1997, Neuroscience.
[196] G. Sedvall,et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. , 1997, Brain : a journal of neurology.
[197] B. Rosen,et al. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10 , 1997, Annals of neurology.
[198] P Boesiger,et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. , 1996, Brain : a journal of neurology.
[199] M. Hayden,et al. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract , 1996, Nature Genetics.
[200] M. Beal,et al. Chronic 3-Nitropropionic Acid Treatment in Baboons Replicates the Cognitive and Motor Deficits of Huntington’s Disease , 1996, The Journal of Neuroscience.
[201] J. Cooper,et al. Mitochondrial defect in Huntington's disease caudate nucleus , 1996, Annals of neurology.
[202] P. Sanberg,et al. Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease , 1995, Brain Research.
[203] Virginia E. Papaioannou,et al. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue , 1995, Nature Genetics.
[204] Peer Bork,et al. HEAT repeats in the Huntington's disease protein , 1995, Nature Genetics.
[205] F. Leblhuber,et al. Serum dehydroepiandrosterone and cortisol measurements in Huntington's chorea , 1995, Journal of the Neurological Sciences.
[206] A. Joyner,et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. , 1995, Science.
[207] M. Beal,et al. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[208] M. Perutz,et al. Incorporation of glutamine repeats makes protein oligomerize: implications for neurodegenerative diseases. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[209] S. Floresco,et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes , 1995, Cell.
[210] D. Steindler,et al. DNA End Labeling (TUNEL) in Huntington's Disease and Other Neuropathological Conditions , 1995, Experimental Neurology.
[211] M. Dragunow,et al. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes , 1995, Neuroreport.
[212] C. Portera-Cailliau,et al. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[213] D. Thorley-Lawson,et al. A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.
[214] John Calvin Reed,et al. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.
[215] S. Folstein,et al. Early Loss of Neostriatal Striosome Neurons in Huntington's Disease , 1995, Journal of neuropathology and experimental neurology.
[216] P. Sanberg,et al. Intrastriatal 3-nitropropionic acid: a behavioral assessment. , 1994, Neuroreport.
[217] J T Finch,et al. Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[218] T. Bolwig,et al. A Study of Psychiatric Morbidity in Patients with Huntington's Disease, Their Relatives, and Controls , 1993, British Journal of Psychiatry.
[219] B. Rosen,et al. Evidence for irnnairment of energy metabofism in vivo in Huntington's disease using localized 1H NMR spectroscopy , 1993, Neurology.
[220] H. Herzog,et al. Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease , 1993, Journal of Neurology.
[221] B. Hyman,et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[222] B. Hyman,et al. Age‐Dependent Striatal Excitotoxic Lesions Produced by the Endogenous Mitochondrial Inhibitor Malonate , 1993, Journal of neurochemistry.
[223] Manish S. Shah,et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.
[224] Elsdon Storey,et al. Excitotoxin Lesions in Primates as a Model for Huntington's Disease: Histopathologic and Neurochemical Characterization , 1993, Experimental Neurology.
[225] B. Rosen,et al. Age‐Dependent Vulnerability of the Striatum to the Mitochondrial Toxin 3‐Nitropropionic Acid , 1993, Journal of neurochemistry.
[226] J. Penney,et al. Preferential loss of striato‐external pallidal projection neurons in presymptomatic Huntington's disease , 1992, Annals of neurology.
[227] I. Heuser,et al. The limbic-hypothalamic-pituitary-adrenal axis in Huntington's disease , 1991, Biological Psychiatry.
[228] H. Kremer,et al. The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington's disease , 1991, Neuroscience Letters.
[229] M. Beal,et al. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[230] Scott T. Grafton,et al. A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease , 1990, Annals of neurology.
[231] H. Herzog,et al. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. , 1990, Brain : a journal of neurology.
[232] Y. Agid,et al. Mitochondrial function and parental sex effect in Huntington's disease , 1990, The Lancet.
[233] A. Reiner,et al. The patterns of neurotransmitter and neuropeptide co-occurrence among striatal projection neurons: conclusions based on recent findings , 1990, Brain Research Reviews.
[234] J. Parks,et al. Evidence for a defect in NADH , 1990, Neurology.
[235] E Maran,et al. Atrophy of the Hypothalamic Lateral Tuberal Nucleus in Huntington's Disease , 1990, Journal of neuropathology and experimental neurology.
[236] J. Penney,et al. The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.
[237] Hitoshi Takahashi,et al. A quantitative investigation of the substantia nigra in Huntington's disease , 1989, Annals of neurology.
[238] J. Penney,et al. Differential loss of striatal projection neurons in Huntington disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[239] P. Thompson,et al. The coexistence of bradykinesia and chorea in Huntington's disease and its implications for theories of basal ganglia control of movement. , 1988, Brain : a journal of neurology.
[240] R. Ferrante,et al. Tyrosine hydroxylase-like immunoreactivity is distributed in the matrix compartment of normal human and Huntington's disease striatum , 1987, Brain Research.
[241] Joseph B. Martin,et al. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease , 1987, Brain Research.
[242] J. Mazziotta,et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. , 1987, The New England journal of medicine.
[243] Joseph B. Martin,et al. Topography of enkephalin, substance P and acetylcholinesterase staining in Huntington's disease striatum , 1986, Neuroscience Letters.
[244] M. Hayden,et al. Positron emission tomography in the early diagnosis of Huntington's disease , 1986, Neurology.
[245] Joseph B. Martin,et al. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.
[246] Ira Shoulson,et al. Huntington's disease in Venezuela , 1986, Neurology.
[247] R. Ferrante,et al. Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.
[248] J. B. Martin,et al. Selective sparing of a class of striatal neurons in Huntington's disease. , 1985, Science.
[249] E. Bird,et al. Regional Mitochondrial Respiratory Activity in Huntington's Disease Brain , 1985, Journal of neurochemistry.
[250] G. Reynolds,et al. Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and γ-glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases , 1985, Journal of the Neurological Sciences.
[251] L. Farrer. Diabetes mellitus in Huntington disease , 1985, Clinical genetics.
[252] S. Folstein,et al. Clinical correlates of dementia and disability in Huntington's disease. , 1984, Journal of clinical neuropsychology.
[253] C. Nahmias,et al. Reduced striatal glucose consumption and prolonged reaction time are early features in Huntington's disease , 1984, Journal of the Neurological Sciences.
[254] S. Folstein,et al. The association of affective disorder with Huntington's Disease in a case series and in families , 1983, Psychological Medicine.
[255] C. Markham,et al. Cerebral metabolism and atrophy in huntington's disease determined by 18FDG and computed tomographic scan , 1982, Annals of neurology.
[256] E. Chiu,et al. Causes of death in Huntington's Disease , 1982, The Medical journal of Australia.
[257] H. Fibiger,et al. BODY WEIGHT AND DIETARY FACTORS IN HUNTINGTON'S DISEASE PATIENTS COMPARED WITH MATCHED CONTROLS , 1981, The Medical journal of Australia.
[258] P. Swanson,et al. Biochemical abnormalities in Huntington's chorea brains , 1974, Neurology.
[259] R. Terry,et al. STUDIES ON BRAIN BIOPSIES OF PATIENTS WITH HUNTINGTON'S CHOREA , 1974, Journal of neuropathology and experimental neurology.
[260] D. Sax,et al. Increased frequency of diabetes mellitus in patients with Huntington's chorea. , 1972, Lancet.
[261] K. Dewhurst,et al. Socio-Psychiatric Consequences of Huntington's Disease , 1970, British Journal of Psychiatry.
[262] Matthew Menear,et al. Brain imaging and cognitive dysfunctions in Huntington's disease. , 2006, Journal of psychiatry & neuroscience : JPN.
[263] Steven P Gygi,et al. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. , 2005, Nature.
[264] H. Tanila,et al. Orexin loss in Huntington's disease. , 2005, Human molecular genetics.
[265] L. Goldstein,et al. Polyglutamine diseases and transport problems: deadly traffic jams on neuronal highways. , 2005, Archives of neurology.
[266] V. Hachinski,et al. Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis. Authors' reply , 2004 .
[267] M. Marsh,et al. The on-off story of protein palmitoylation. , 2003, Trends in cell biology.
[268] R. Schwarcz,et al. 3-Hydroxykynurenine and quinolinate: pathogenic synergism in early grade Huntington's disease? , 2003, Advances in experimental medicine and biology.
[269] M. Tsai,et al. Neogenesis of beta-cells in adult BETA2/NeuroD-deficient mice. , 2002, Molecular endocrinology.
[270] R. Kopito,et al. Impairment of the ubiquitin-proteasome system by protein aggregation. , 2001, Science.
[271] S. Hersch,et al. Huntington aggregates may not predict neuronal death in Huntington's disease. , 1999, Annals of neurology.
[272] B R Rosen,et al. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. , 1993, Neurology.
[273] Ira Shoulson,et al. Huntington's disease in venezuela: 7 years of follow‐up on symptomatic and asymptomatic individuals , 1990, Movement disorders : official journal of the Movement Disorder Society.
[274] S. Folstein,et al. Huntington disease in Maryland: clinical aspects of racial variation. , 1987, American journal of human genetics.
[275] S. W. Davies,et al. No evidence for preservation of somatostatin-containing neurons after intrastriatal injections of quinolinic acid , 1987, Nature.
[276] Michel Cyr,et al. The FASEB Journal • FJ Express Full-Length Article Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin , 2022 .
[277] D. Joel,et al. Full-length Review , 2022 .